vs

Side-by-side financial comparison of NEKTAR THERAPEUTICS (NKTR) and WEST BANCORPORATION INC (WTBA). Click either name above to swap in a different company.

WEST BANCORPORATION INC is the larger business by last-quarter revenue ($26.9M vs $21.8M, roughly 1.2× NEKTAR THERAPEUTICS). WEST BANCORPORATION INC runs the higher net margin — 39.2% vs -165.4%, a 204.7% gap on every dollar of revenue. On growth, WEST BANCORPORATION INC posted the faster year-over-year revenue change (16.6% vs -25.3%). WEST BANCORPORATION INC produced more free cash flow last quarter ($12.4M vs $-65.0M). Over the past eight quarters, WEST BANCORPORATION INC's revenue compounded faster (17.3% CAGR vs 0.4%).

Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, e...

West Bancorporation Inc. is a regional financial holding company headquartered in the U.S. Midwest, primarily serving markets across Iowa and Minnesota. It provides a full suite of personal and commercial banking services, including deposit accounts, mortgage loans, business lending, and wealth management solutions for individual consumers, small-to-medium enterprises, and local organizational clients.

NKTR vs WTBA — Head-to-Head

Bigger by revenue
WTBA
WTBA
1.2× larger
WTBA
$26.9M
$21.8M
NKTR
Growing faster (revenue YoY)
WTBA
WTBA
+41.9% gap
WTBA
16.6%
-25.3%
NKTR
Higher net margin
WTBA
WTBA
204.7% more per $
WTBA
39.2%
-165.4%
NKTR
More free cash flow
WTBA
WTBA
$77.4M more FCF
WTBA
$12.4M
$-65.0M
NKTR
Faster 2-yr revenue CAGR
WTBA
WTBA
Annualised
WTBA
17.3%
0.4%
NKTR

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
NKTR
NKTR
WTBA
WTBA
Revenue
$21.8M
$26.9M
Net Profit
$-36.1M
$10.6M
Gross Margin
Operating Margin
-126.9%
50.0%
Net Margin
-165.4%
39.2%
Revenue YoY
-25.3%
16.6%
Net Profit YoY
-596.9%
34.8%
EPS (diluted)
$-4.67
$0.61

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NKTR
NKTR
WTBA
WTBA
Q1 26
$26.9M
Q4 25
$21.8M
$24.2M
Q3 25
$11.8M
$25.0M
Q2 25
$11.2M
$23.8M
Q1 25
$10.5M
$23.1M
Q4 24
$29.2M
$20.9M
Q3 24
$24.1M
$20.3M
Q2 24
$23.5M
$19.6M
Net Profit
NKTR
NKTR
WTBA
WTBA
Q1 26
$10.6M
Q4 25
$-36.1M
$7.4M
Q3 25
$-35.5M
$9.3M
Q2 25
$-41.6M
$8.0M
Q1 25
$-50.9M
$7.8M
Q4 24
$7.3M
$7.1M
Q3 24
$-37.1M
$6.0M
Q2 24
$-52.4M
$5.2M
Gross Margin
NKTR
NKTR
WTBA
WTBA
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
72.7%
Q3 24
81.6%
Q2 24
58.5%
Operating Margin
NKTR
NKTR
WTBA
WTBA
Q1 26
50.0%
Q4 25
-126.9%
39.6%
Q3 25
-268.6%
45.8%
Q2 25
-324.2%
43.4%
Q1 25
-425.8%
43.4%
Q4 24
49.2%
30.9%
Q3 24
-142.4%
36.6%
Q2 24
-211.9%
32.6%
Net Margin
NKTR
NKTR
WTBA
WTBA
Q1 26
39.2%
Q4 25
-165.4%
30.7%
Q3 25
-301.3%
37.3%
Q2 25
-372.2%
33.5%
Q1 25
-486.4%
34.0%
Q4 24
24.9%
34.0%
Q3 24
-153.6%
29.3%
Q2 24
-222.9%
26.5%
EPS (diluted)
NKTR
NKTR
WTBA
WTBA
Q1 26
$0.61
Q4 25
$-4.67
$0.44
Q3 25
$-1.87
$0.55
Q2 25
$-2.95
$0.47
Q1 25
$-0.24
$0.46
Q4 24
$-2.07
$0.41
Q3 24
$-2.66
$0.35
Q2 24
$-3.76
$0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NKTR
NKTR
WTBA
WTBA
Cash + ST InvestmentsLiquidity on hand
$15.1M
$362.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$89.8M
$270.7M
Total Assets
$280.4M
$4.0B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NKTR
NKTR
WTBA
WTBA
Q1 26
$362.0M
Q4 25
$15.1M
$471.1M
Q3 25
$41.0M
$232.9M
Q2 25
$43.0M
$345.2M
Q1 25
$38.9M
Q4 24
$44.3M
$243.5M
Q3 24
$30.1M
Q2 24
$27.9M
Stockholders' Equity
NKTR
NKTR
WTBA
WTBA
Q1 26
$270.7M
Q4 25
$89.8M
$266.0M
Q3 25
$85.1M
$255.1M
Q2 25
$-24.2M
$240.9M
Q1 25
$13.7M
$237.9M
Q4 24
$60.7M
$227.9M
Q3 24
$48.9M
$235.4M
Q2 24
$79.7M
$223.9M
Total Assets
NKTR
NKTR
WTBA
WTBA
Q1 26
$4.0B
Q4 25
$280.4M
$4.1B
Q3 25
$301.3M
$4.0B
Q2 25
$207.5M
$4.1B
Q1 25
$256.2M
$4.0B
Q4 24
$303.9M
$4.0B
Q3 24
$308.0M
$4.0B
Q2 24
$343.3M
$4.0B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NKTR
NKTR
WTBA
WTBA
Operating Cash FlowLast quarter
$-65.0M
$12.9M
Free Cash FlowOCF − Capex
$-65.0M
$12.4M
FCF MarginFCF / Revenue
-298.0%
46.0%
Capex IntensityCapex / Revenue
0.1%
1.8%
Cash ConversionOCF / Net Profit
1.22×
TTM Free Cash FlowTrailing 4 quarters
$-208.7M
$79.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NKTR
NKTR
WTBA
WTBA
Q1 26
$12.9M
Q4 25
$-65.0M
$46.5M
Q3 25
$-48.8M
$11.4M
Q2 25
$-45.7M
$13.5M
Q1 25
$-49.1M
$9.7M
Q4 24
$-46.2M
$39.8M
Q3 24
$-43.9M
$12.9M
Q2 24
$-37.7M
$10.0M
Free Cash Flow
NKTR
NKTR
WTBA
WTBA
Q1 26
$12.4M
Q4 25
$-65.0M
$43.2M
Q3 25
$-48.9M
$10.8M
Q2 25
$-45.8M
$12.8M
Q1 25
$-49.1M
$8.3M
Q4 24
$-46.6M
$13.7M
Q3 24
$-44.6M
$7.0M
Q2 24
$-37.9M
$2.7M
FCF Margin
NKTR
NKTR
WTBA
WTBA
Q1 26
46.0%
Q4 25
-298.0%
178.3%
Q3 25
-414.5%
43.0%
Q2 25
-409.6%
53.6%
Q1 25
-469.0%
35.7%
Q4 24
-159.9%
65.6%
Q3 24
-184.9%
34.2%
Q2 24
-161.3%
14.0%
Capex Intensity
NKTR
NKTR
WTBA
WTBA
Q1 26
1.8%
Q4 25
0.1%
13.7%
Q3 25
1.0%
2.6%
Q2 25
0.3%
3.2%
Q1 25
0.0%
6.5%
Q4 24
1.6%
125.3%
Q3 24
2.8%
29.4%
Q2 24
0.8%
37.1%
Cash Conversion
NKTR
NKTR
WTBA
WTBA
Q1 26
1.22×
Q4 25
6.26×
Q3 25
1.23×
Q2 25
1.70×
Q1 25
1.24×
Q4 24
-6.36×
5.61×
Q3 24
2.17×
Q2 24
1.93×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons